Mode
Text Size
Log in / Sign up
N/A N=196

Retrospective Simplex High Viscosity (HV) Bone Cement Study

Arthritis Knee · Aseptic Loosening

Enrolled (actual)
196
Serious AEs
15.8%
Results posted
Jan 2026
Primary outcome: Primary: Number of Participants With Successful Application of Bone Cement — 95; 101 Participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Simplex HV/Gentamicin Simplex HV bone cement (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Stryker Orthopaedics
Primary completion
Sep 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Successful Application of Bone Cement
95; 101
SECONDARY
Knee Society Score (KSS) Pain Motion Score: Range of Motion
108.59; 101.16; 110.48; 110.32; 113.37; 114.81
SECONDARY
KSS Pain Motion Score: Pain
0; 1; 11; 0; 34; 6
SECONDARY
KSS Function Score: Walking Aids
23; 12; 3; 1; 0; 1
SECONDARY
KSS Function Score: Walking
1; 0; 48; 13; 0; 7
SECONDARY
KSS Function Score: Stairs
22; 0; 12; 2; 0; 0
SECONDARY
Oxford Knee Score (OKS) Results
18.96; 39.27; 39.38
SECONDARY
KSS Pain Motion Score: Stability
87; 1; 81; 0; 52; 0

Summary

This study is a retrospective multicenter study to review the use of Simplex High Viscosity Bone Cement in Primary Total Knee Arthroplasty

Eligibility Criteria

Inclusion Criteria

  • The Patient is age 18 or over at time of study device implantation
  • Patients who have undergone primary Triathlon Total Knee Arthroplasty in which Simplex HV/Simplex HV Gentamicin was indicated for fixation and used on label
  • Patients who have been followed for at least 24 months postoperatively

Exclusion Criteria

  • Patients who have undergone revision surgery
  • Patients who have undergone bilateral Knee Arthroplasty
  • Patients contraindicated for either the devices implanted, or the cement used, according to medical history review and instructions for use
  • Patient has a cementless tibial baseplate.
  • Patient has an active or suspected latent infection in or about the affected knee joint
  • Patient has muscle loss or neuromuscular impairment in the affected limb that would create an unjustifiable risk
  • Patient is immunologically suppressed or receiving steroids in excess of normal physiological requirements (e.g. > 30 days)
  • Patient has a known hypersensitivity to any of the cements constituents or in patients with severe renal failure
  • Patient is a prisoner
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05659329). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search